On December 27th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) – a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation.
This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.
On December 27th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) – a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation.
by Teri Woodhull I am so excited for a new FORCE program called XRAY-Behind the Ovarian Cancer Headlines! My ovarian cancer was already advanced by the time it was diagnosed and I believe that research has played a big role in my nine-year survival. Admittedly, I’m a bit of a research junkie. I attend scientific … + read more
Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.
FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.